BACKGROUND: Previous research has shown that infliximab (IFX) is effective in the management of moderate to severe active ulcerative colitis (UC). Latin American studies are lacking. AIM: To evaluate the efficacy of IFX treatment (including corticosteroid withdrawal, complete mucosal healing, colectomy and hospitalization rates) in patients with moderate to severe UC. METHODS: A retrospective and descriptive study was conducted on patients with UC in Medellín (Colombia). We included patients steroid dependent or refractory to conventional treatment. RESULTS: Between October 2005 and July 2011, 28 patients with moderate to severe UC received IFX infusions; the median of the follow-up was 27.4 months (range: 1-69 months). Twenty-four patients (86%) had a short-term primary response, whilst 19 (68%) achieved initial clinical remission. After 1 year, 17 (71%) out of the 24 patients who had an initial response were also showing a sustained response, and 10 (42%) remained in clinical remission. At 6 months, complete mucosal healing was observed in 29% of patients and endoscopic improvement in 57%. CONCLUSIONS: This is the first study to evaluate the IFX use in patients with moderate to severe active UC in a Latin American population. We found that IFX therapy is effective for inducing clinical remission, and that most patients who had an initial response showed a long-term sustained response.
BACKGROUND: Previous research has shown that infliximab (IFX) is effective in the management of moderate to severe active ulcerative colitis (UC). Latin American studies are lacking. AIM: To evaluate the efficacy of IFX treatment (including corticosteroid withdrawal, complete mucosal healing, colectomy and hospitalization rates) in patients with moderate to severe UC. METHODS: A retrospective and descriptive study was conducted on patients with UC in Medellín (Colombia). We included patientssteroid dependent or refractory to conventional treatment. RESULTS: Between October 2005 and July 2011, 28 patients with moderate to severe UC received IFX infusions; the median of the follow-up was 27.4 months (range: 1-69 months). Twenty-four patients (86%) had a short-term primary response, whilst 19 (68%) achieved initial clinical remission. After 1 year, 17 (71%) out of the 24 patients who had an initial response were also showing a sustained response, and 10 (42%) remained in clinical remission. At 6 months, complete mucosal healing was observed in 29% of patients and endoscopic improvement in 57%. CONCLUSIONS: This is the first study to evaluate the IFX use in patients with moderate to severe active UC in a Latin American population. We found that IFX therapy is effective for inducing clinical remission, and that most patients who had an initial response showed a long-term sustained response.
Authors: Danny J Avalos; Antonio Mendoza-Ladd; Marc J Zuckerman; Mohammad Bashashati; Andres Alvarado; Alok Dwivedi; Oriana M Damas Journal: Dig Dis Sci Date: 2018-03-29 Impact factor: 3.199
Authors: Ana Gutiérrez; Pedro Zapater; Elena Ricart; María González-Vivó; Jordi Gordillo; David Olivares; Isabel Vera; Míriam Mañosa; Javier P Gisbert; Mariam Aguas; Eugenia Sánchez-Rodríguez; Maia Bosca-Watts; Viviana Laredo; Blau Camps; Ignacio Marín-Jiménez; Yamile Zabana; María Dolores Martín-Arranz; Roser Muñoz; Mercè Navarro; Eva Sierra; Lucía Madero; Milagros Vela; José Lázaro Pérez-Calle; Empar Sainz; Xavier Calvet; Lara Arias; Victor Morales; Fernando Bermejo; Luis Fernández-Salazar; Manuel Van Domselaar; Luisa De Castro; Cristina Rodríguez; Carmen Muñoz-Villafranca; Rufo Lorente; Montserrat Rivero; Eva Iglesias; Belén Herreros; David Busquets; Joan Riera; María Pilar Martínez-Montiel; Marta Roldón; Oscar Roncero; Esther Hinojosa; Mónica Sierra; Jesús Barrio; Ruth De Francisco; José Huguet; Olga Merino; Daniel Carpio; Daniel Ginard; Fernando Muñoz; Marta Piqueras; Pedro Almela; Federico Argüelles-Arias; Guillermo Alcaín; Luis Bujanda; Noemí Manceñido; Alfredo J Lucendo; Pilar Varela; Iago Rodríguez-Lago; Laura Ramos; Laura Sempere; Eva Sesé; Manuel Barreiro-de Acosta; Eugeni Domènech; Rubén Francés Journal: Front Med (Lausanne) Date: 2022-02-01